Nomas Global Investments LLC, Invests USD 612 Million in Beaufond Plc for Strategic Growth

DIFC, UAE - Dec. 12, 2024 - PRLog -- Beaufond Plc, a leading global pharmaceutical contract manufacturer, has announced that Nomas Global Investments, a Special Purpose Vehicle (SPV) of H. H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan, a member of the Royal Family of Abu Dhabi, has signed a Memorandum of Understanding to invest USD 612 million in exchange for a strategic stake in the company. This investment, which values Beaufond at USD 4.36 billion, marks the beginning of a new chapter for the company as it seeks long-term growth and success in the pharmaceutical sector.

The investment signals a strong partnership with the member of Abu Dhabi royal family, reinforcing Beaufond's global market position and enhancing its ability to meet increasing demand for high-quality medicines. This collaboration will accelerate Beaufond's global expansion, improve its research and manufacturing capabilities, and explore new market opportunities.

Key Highlights:

• Investment: USD 612 million from the Royal Family of Abu Dhabi

· Valuation: Beaufond now valued at USD 4.36 billion

· Strategic Partnership: Long-term collaboration to drive global expansion

· Future Focus: Strengthening Beaufond's global presence and research in pharmaceutical manufacturing

As part of this strategic growth phase, Beaufond is investing in an Integrated Formulation Unit, which will produce solid oral tablets, capsules, ointments, and other oral dosage forms. This new facility will streamline production and enhance manufacturing efficiency, enabling Beaufond to meet global demand for high-quality medicines more effectively.

H.H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan commented, "This investment reflects our commitment to supporting strategic industries in the UAE and reinforcing the nation's position as a global healthcare innovation hub. Our partnership with Beaufond will drive sustainable economic growth and create high-quality job opportunities for UAE nationals."

Beaufond's Coo, A. Kumar, expressed excitement about the partnership, stating, "We are honored to welcome the Royal Family of Abu Dhabi as a strategic partner. This collaboration provides the resources necessary for our global expansion. Additionally, the new Integrated Formulation Unit will enable us to meet the growing global demand for effective pharmaceutical solutions, reinforcing our commitment to excellence."

The Integrated Formulation Unit is expected to be operational by 2025-2026, playing a key role in scaling Beaufond's manufacturing capabilities and meeting international standards for safety and quality. The project will also create hundreds of new jobs and contribute to the development of a skilled workforce in the UAE's pharmaceutical sector.

About Beaufond Plc
Beaufond Plc is a global leader in pharmaceutical contract manufacturing, specializing in Api and multi-commodity trading. The company achieved a turnover of USD2.26 billion in 2024, driven by strategic initiatives and a strong market presence.
http://www.beaufond.com